A 66-year-old white woman experienced four embolic strokes with large vessel occlusion over two years before being diagnosed with primary antiphospholipid syndrome in 2024. Despite repeated successful mechanical thrombectomies and initial treatment for atrial fibrillation, the patient only stabilized after switching to Vitamin K antagonist therapy.
The case, detailed in a report published June 26, 2024, in Brain Circulation (10(2):184-187), highlights a critical diagnostic gap in elderly patients. The report was authored by Anatoli Anastasiadi et al., with contributors from several institutions including the Department of Neurology, Department of Nephrology, Department of Cardiology, and Department of Neuroradiology at Klinikum Stuttgart, Katharinen Hospital in Stuttgart, Germany, as well as the Department of Neurologische Klinik, Medizinische Fakultät Mannheim, Universität Heidelberg, Germany. While up to 20% of strokes in individuals under 50 are associated with antiphospholipid syndrome (APS), the condition is considered a very seldom cause of stroke in those over 50.
Diagnostic Failures and the Shift to Vitamin K Antagonists
For two years, the patient’s recurrent embolic strokes were initially attributed to atrial fibrillation. This led clinicians to treat her with direct oral anticoagulants (DOACs). However, the strokes continued to recur despite this medication.
The turning point occurred when the patient was diagnosed with primary APS, specifically linked to isolated anti-beta 2-glycoprotein antibodies. Once medical providers initiated Vitamin K antagonist therapy, the patient experienced no further strokes. The authors conclude that for recurrent embolic stroke despite oral anticoagulation, late-onset APS might be considered a rare etiology also in the elderly.
This outcome underscores a specific management challenge: not all anticoagulants are equal in APS. While Vitamin K antagonists are the traditional standard for maintaining an international normalised ratio of 2.0–3.0, the use of DOACs in this specific case failed to prevent recurrent large vessel occlusions.
Clinical Criteria and Antibody Risk Profiles
Antiphospholipid syndrome is an acquired autoimmune disorder characterized by pregnancy morbidity and recurrent venous or arterial thrombosis in the presence of persistent antiphospholipid antibodies. Diagnosing APS requires a combination of clinical evidence—such as adverse obstetric outcomes or documented thromboembolic events—and laboratory confirmation.
- Lupus anticoagulant (LA): A functional assay detecting antibodies that prolong clotting times.
- Anticardiolipin antibodies.
- Anti-β2-glycoprotein I antibodies: The principal antigen recognized by pathogenic antibodies.
The risk of recurrence is not uniform across all patients. Those with a triple-positive status—meaning they possess all three antibody types—face higher rates of recurrence. This risk stratification, which incorporates antibody profile intensity, helps providers determine the intensity of the required anticoagulation.
Emerging Therapeutic Paradigms Beyond Anticoagulation
While the 66-year-old patient was stabilized with traditional anticoagulants, research is shifting toward targeting the innate immune system to prevent the formation of clots. Standard management for those with obstetric complications may employ heparin and low-dose aspirin to improve live-birth rates.
One significant area of study involves neutrophil extracellular traps (NETs), which are web-like chromatin structures that contribute to thrombus formation. Research cited by Nature Portfolio indicates that selective agonism of the adenosine A2A receptor can suppress these traps and attenuate thrombosis in animal models. By potentiating cyclic AMP signalling, both specific receptor agonists and the antithrombotic agent dipyridamole have reduced vascular occlusion in mice challenged with pathogenic antibodies.
Another frontier is epigenetic analysis. Recent findings reveal that enhanced trimethylation of histone H3 at lysine 4 in monocytes drives the overexpression of the transcription factor FOXJ2. This process activates the SLAMF8/TREM1 axis, which amplifies both inflammation and thrombosis. In vitro tests show that pharmacological inhibition of this methylation event can reduce thromboinflammatory markers and attenuate vascular lesions in a murine antiphospholipid model.
Additional management strategies include:
- Adjunctive therapies: The use of statins or hydroxychloroquine to modulate inflammation.
- Targeted interventions: Strategies against neutrophil extracellular trap formation or complement activation.
- Individualized care: Multidisciplinary surveillance and the address of cardiovascular risk factors.
The discrepancy between the 66-year-old patient’s failure on DOACs and the broader research on these drugs remains a point of clinical interest. While a multicentre randomised trial assessed rivaroxaban against warfarin for secondary prevention of venous thromboembolism in antiphospholipid patients, the source notes that although thrombin-generation parameters differed, no increase in clinical events was found in the rivaroxaban group.
The central uncertainty remaining for clinicians is the precise identification of which selected thrombotic phenotypes can safely use DOACs and which require the stricter, more traditional Vitamin K antagonists to prevent catastrophic events like the four strokes seen in the Stuttgart case. Readers should consult qualified healthcare professionals for medical guidance regarding the diagnosis and treatment of antiphospholipid syndrome.
Keep reading
